葡萄球菌中毒性休克毒素的分离纯化及其体外抗肝癌活性分析

采用固体膜进行TSST-1的产毒培养,然后从金葡菌产毒产物中经CM纤维素离子交换层析、SephadexG-75、Sephacryl S-200三步纯化,成功地获得了纯度为95.3％的毒素,SDS-PAGE呈现单一条带,与其对应抗血清有免疫学特异反应,不含核酸、糖和其它肠毒素等物质。与同类方法相比,该方法步骤少、快速、简便。对其体外抗肝癌活性进行了分析,首次证明即使TSST-1的浓度为10^-8g/L仍然对人肝癌细胞有显著抑制作用。     

葡萄球菌B型肠毒素突变体的分子设计、高效表达与活性初步研究

葡萄球菌B型肠毒素（SEB0是重要的超抗原,依据SEB分子的晶体结构并结合表面分析,模拟设计了与MHCⅡ类分子和TCR VB区亲合力降低的三位点突变体mSEB(Y89A,C93S,Y94A)。通过PCR重叠延伸法获得突变体基因,导入PBV220载体中,于E.coliDH5α中获得高效表达,纯化的突变毒素T细胞激活活性仅为野生型毒素的1/5左右。     

葡萄球菌A型肠毒素的高效表达和分离纯化

根据已知葡萄球菌A型肠毒素 (SEA)的基因序列 ,用PCR从产毒标准株S .aureusFRI 10 0中扩增得到约70 0的SEA基因片段 ,并将该片段克隆至表达载体 pBV2 2 0中 ,实现了高效表达。表达产物以可溶性形式存在 ,表达的毒素用CM SephroseFF离子交换层析进行纯化 ,获得了高纯度的重组SEA ,SDS PAGE显示单一条带。ELISA试验证明所获重组SEA具有与天然SEA相似的免疫学性质。     

葡萄球菌B型肠毒素突变体SEB(Y89A,C93S,Y94A)对小鼠的免疫保护作用

目的:评价葡萄球菌B型肠毒素(SEB)突变体SEB(Y89A,C93S,Y94A)作为超抗原疫苗候选分子对小鼠的免疫保护作用。方法:制备具有一定纯度和活性的突变体蛋白SEB(Y89A,C93S,Y94A)样品,灭活后免疫BALB/c小鼠,待小鼠抗体水平上升后,再以野生型SEB(wt-SEB)攻击用D-半乳糖胺致敏的BALB/c小鼠,评价该突变体蛋白的免疫保护作用。结果:突变体蛋白SEB(Y89A,C93S,Y94A)在重组大肠杆菌DH5α中得到表达,主要以包涵体形式存在,经变性、复性、SephacrylS200凝胶过滤,制备成较高纯度(95%)的、具有与wt-SEB相同抗原性的突变体蛋白样品,甲醛灭活后免疫BALB/c小鼠至4周,ELISA法测定小鼠抗体效价水平可达106;进而以wt-SEB攻毒,在达8倍LD50的攻击下,阴性对照小鼠在24h内全部死亡,而SEB(Y89A,C93S,Y94A)组与wt-SEB组小鼠至48h仍有存活。结论:突变体蛋白的保护效果与wt-SEB相类似,有望成为SEB减毒疫苗候选分子。     

从噬菌体表面展示肽库中筛选葡萄球菌B型肠毒素抑制剂

通过生物淘选,从噬菌体表面展示12肽肽库中筛选能与葡萄球菌B型肠毒素(staphylococcalenterotoxinB ,SEB)结合且能抑制其肠毒活性的特异性短肽.采用Phage ELISA和MTT鉴定所得目的肽的亲和性;根据优势噬菌体阳性克隆序列合成相应多肽.利用竞争ELISA研究合成肽与SEB单克隆抗体竞争结合SEB的情况;通过动物实验考察其抑制SEB的超抗原特性和肠毒活性情况.筛选所得短肽在一定浓度范围内可以抑制SEB对鼠脾淋巴细胞的激活;合成肽与SEB质量比为16 0∶1时,合成肽可较好地抑制SEB对乳猫的肠毒活性,并对SEB引起的小鼠致死具有明显保护作用.结果表明,初步得到了能与SEB特异结合并能抑制SEB超抗原特性和肠毒活性的短肽,为进一步研制SEB高效抑制剂奠定了基础.     

低出血倾向、低免疫原性葡激酶mSAK(K130T,K135R)的表达、纯化与活性测定

为了有效降低葡激酶应用的副作用,构建低出血倾向、低免疫原性葡激酶突变体,高效表达纯化后进行活性鉴定,以野生型重组葡激酶基因为模板,PCR法引入突变位点(K130T,K135R),并将该片段克隆测序鉴定后,克隆至表达载体pBV220,构建低免疫原性葡激酶突变体.表达后的蛋白用Q-SepharoseFF柱与SephacrylS-200进行纯化,纤维蛋白溶圈法进行活性测定,体外抗体中和试验与豚鼠免疫试验测定突变体蛋白的免疫原性,同时进行动物体内出血倾向观察.测序结果表明,相应位点获得突变,无非特异性突变,将突变后的片段连接pBV220导入大肠杆菌热激诱导获得了高效表达,表达产物占菌体总蛋白的40%~50%.产物主要以可溶性形式存在,经两步纯化后的蛋白的纯度可达98%以上.活性测定试验表明,该突变体的活性较野生型葡激酶稍低,体外中和抗体试验和豚鼠免疫试验证明免疫原性大为下降,豚鼠的皮肤出血以及肺部病理切片均显示该突变体蛋白引起的出血倾向明显降低.     

B3(ds-scFv)靶向超抗原的制备及活性鉴定

To construct the expression vector of a recombinant toxin composed of a disulfide stable single-chain antibody from mAbB3 and SEA(D227A),the binding ability and cytotoxicity of the purified renatured products against the B3 positive carcinoma cells was examined. The VH and VL fragments of the mAbB3 were ligated by overlap PCR, the PCR product was cloned to the pET22b expression vector, then the SEA fragment was inserted into the B3dsscFv-pET22b expression vector which was digested by the same restriction enzymes. The expression plasmid was identified by restriction endonucleases digestion and transformed into E.coli BL21(DE3) followed by IPTG induction. The inclusion body was purified through SP-Sepharose cation exchange column after denaturing and refolding and the binding and cytotoxic ability of the purified products was examined by cell-ELISA and non-radioactive cell proliferation assay seperately. The expression vector B3dsscFv-SEA-pET was constructed successfully and the expression product exists mainly in the inclusion body, amounting to 33% of the total protein. The refolding product remains the binding ability of the single-chain antibody and has cytotoxic effect on HT-29 colon carcinoma cells. The stability assay showed that the resulting protein was stable at 37℃. This genetically engineered B3dsscFv-SEA fusion protein has bifunction of tumor targeting and tumor cell killing and promises to be an effective reagent for tumor targeted immunotherapy.     

临床病原菌种类及耐药性监测

目的 探讨病原菌种类及其对抗菌药物的耐的耐药状况。方法 收集１９９８年１月－１９９９年１２月临床感染标本分离的病原菌并分析其种类,药敏试验采用Ｋｉｒｂｙ－Ｂａｕｅｒ纸片扩散法。结果 １１８２株病原菌,革兰氏阳性球菌６０４株（５１．１％）,革兰氏阴性杆菌５７８株（４８．９％）。病原菌以金黄一萄球菌、大肠埃希菌、表皮葡萄球菌、铜绿假单胞菌最多见。去甲万古霉素、阿米卡星、新霉素对革兰氏阳性球菌抗菌作用较